Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity

被引：0

作者：

Howard, S. ^{[1
]}

Berdini, V. ^{[2
]}

Curry, J. ^{[3
]}

Gill, A. L. ^{[1
]}

Richardson, C. J. ^{[3
]}

Rees, D. ^{[1
]}

Reule, M. ^{[3
]}

Tisi, D. ^{[4
]}

Wyatt, P. ^{[1
]}

Fazal, L. ^{[3
]}

机构：

[1] Astex Therapeut, Med Chem, Cambridge, England

[2] Astex Therapeut, Computat Chem, Cambridge, England

[3] Astex Therapeut, Biol, Cambridge, England

[4] Astex Therapeut, Struct Biol, Cambridge, England

来源：

EJC SUPPLEMENTS | 2008年 / 6卷 / 12期

关键词：

D O I：

10.1016/S1359-6349(08)72221-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：93 / 93

页数：1

共 50 条

[41] Dasatinib (BMS-354825): A multi-targeted kinase inhibitor with activity against multiple myeloma.
Deng, QW
Mitsiades, N
Negri, J
Wen, ZQ
Rooney, M
Hideshima, T
Chauhan, D
Munshi, NC
Richardson, PG
Lee, FY
Anderson, KC
Mitsiades, CS
BLOOD, 2005, 106 (11) : 451A - 451A
[42] A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
Hay, Annette E.
Murugesan, Alli
DiPasquale, Ashley M.
Kouroukis, Tom
Sandhu, Irwindeep
Kukreti, Vishal
Bahlis, Nizar J.
Lategan, Johan
Reece, Donna E.
Lyons, John F.
Sederias, Joana
Xu, Hao
Powers, Jean
Seymour, Lesley K.
Reiman, Tony
LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1463 - 1466
[43] Analysis of sunitinib malate, a multi-targeted tyrosine kinase inhibitor: A critical review
AboulMagd, Asmaa M.
Abdelwahab, Nada S.
MICROCHEMICAL JOURNAL, 2021, 163
[44] PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity
Soncini, Chiara
Carpinelli, Patrizia
Gianellini, Laura
Fancelli, Daniele
Vianello, Paola
Rusconi, Luisa
Storici, Paola
Zugnoni, Paola
Pesenti, Enrico
Croci, Valter
Ceruti, Roberta
Giorgini, Maria Laura
Cappella, Paolo
Ballinari, Dario
Sola, Francesco
Varasi, Mario
Bravo, Rodrigo
Moll, Juergen
CLINICAL CANCER RESEARCH, 2006, 12 (13) : 4080 - 4089
[45] A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND. 191
Hay, Annette E.
Murugesan, Alli
DiPasquale, Ashley M.
Kouroukis, Tom
Sandhu, Irwindeep
Kukreti, Vishal
Bahlis, Nizar J.
Lategan, Johan
Reece, Donna E.
Lyons, John F.
Sederias, Joana
Powers, Jean
Xu, Hao
Seymour, Lesley K.
Reiman, Anthony
BLOOD, 2014, 124 (21)
[46] SUBSTRATE ACTIVITY SCREENING: A NEW FRAGMENT-BASED METHOD FOR INHIBITOR DISCOVERY
Ellman, J. A.
BIOPOLYMERS, 2009, 92 (04) : 296 - 296
[47] Identification of inhibitors of protein kinase B using fragment-based lead discovery
Saxty, Gordon
Woodhead, Steven J.
Berdini, Valerio
Davies, Thomas G.
Verdonk, Marcel L.
Wyatt, Paul G.
Boyle, Robert G.
Barford, David
Downham, Robert
Garrett, Michelle D.
Carr, Robin A.
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) : 2293 - 2296
[48] Characterisation of aurora kinase inhibitors derived from fragment based lead discovery
Gallagher, Neil
Lyons, John
Curry, Jayne
Reule, Matthias
Berdini, Valerio
Tisi, Dominic
Fazal, Lynsey
Howard, Steven
Wyatt, Paul
Gill, Adrian
CANCER RESEARCH, 2006, 66 (08)
[49] Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues
Kwiatkowski, Jacek
Baburajendran, Nithya
Poulsen, Anders
Liu, Boping
Tee, Doris Hui Ying
Wong, Yun Xuan
Poh, Zhi Ying
ong, Esther H. Q.
Dinie, Nurul
Cherian, Joseph
Jansson, Anna Elisabet
Hill, Jeffrey
Keller, Thomas H.
Hung, Alvin W.
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (03): : 318 - 323
[50] Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors
Li, Rongshi
Martin, Mathew P.
Liu, Yan
Wang, Binglin
Patel, Ronil A.
Zhu, Jin-Yi
Sun, Nan
Pireddu, Roberta
Lawrence, Nicholas J.
Li, Jiannong
Haura, Eric B.
Sung, Shen-Shu
Guida, Wayne C.
Schonbrunn, Ernst
Sebti, Said M.
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (05) : 2474 - 2478

← 1 2 3 4 5 →